

FORM NRC-313M (8-78) 10 CFR 35	U.S. NUCLEAR REGULATORY COMMISSION APPLICATION FOR MATERIALS LICENSE – MEDICAL	Approved: GAO R0557			
INSTRUCTIONS - Complete Items 1 through 26 if this is an initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to: Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee is subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.					
1.a. NAME AND MAILING ADDRESS OF APPLICANT (institution, firm, clinic, physician, etc.) INCLUDE ZIP CODE VA Medical Center 4100 W. Third Street Dayton, Ohio 45428 TELEPHONE NO.: AREA CODE () - -		1.b. STREET ADDRESS(ES) AT WHICH RADIOACTIVE MATERIAL WILL BE USED (If different from 1.a.) INCLUDE ZIP CODE <div style="text-align: center; padding: 20px;">Same</div>			
2. PERSON TO CONTACT REGARDING THIS APPLICATION Khairoon M. Ally, M.D., Chief Nuclear Medicine Service TELEPHONE NO.: AREA CODE (513) 268 6511x2688		3. THIS IS AN APPLICATION FOR: (Check appropriate item) a. <input type="checkbox"/> NEW LICENSE b. <input checked="" type="checkbox"/> AMENDMENT TO LICENSE NO. 34-05015-01 c. <input type="checkbox"/> RENEWAL OF LICENSE NO. _____			
4. INDIVIDUAL USERS (Name individuals who will use or directly supervise use of radioactive material. Complete Supplements A and B for each individual.) Amend to add: Barry Allen Warner, D.O.		5. RADIATION SAFETY OFFICER (RSO) (Name of person designated as radiation safety officer. If other than individual user, complete resume of training and experience as in Supplement A.) Amend to: Bruce Austin, Ph.D.			
6.a. RADIOACTIVE MATERIAL FOR MEDICAL USE					
RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)	ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)
10 CFR 31.11 FOR IN VITRO STUDIES			IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM	x	30
10 CFR 35.100, SCHEDULE A, GROUP I		AS NEEDED	PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES		
10 CFR 35.100, SCHEDULE A, GROUP II		AS NEEDED	PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP III			GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP IV		AS NEEDED	IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA	x	200
10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED	XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.		
10 CFR 35.100, SCHEDULE A, GROUP VI					
6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35, and NEED NOT BE LISTED.)					
ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE		
The purpose of this application is twofold: (1) Add Barry Allen Warner, D.O. as authorized user for I-131 hyperthyroidism and carcinoma only. (2) Change in the Radiation Safety Officer at this facility (See Item #5 above).					

8803080307 880219
 REG3 LIC30

FO. 34-05015-01 PDR
 (8-78)

RECEIVED
 NOV 23 1967
 REGION III

INFORMATION REQUIRED FOR ITEMS 7 THROUGH 23


For Items 7 through 23, check the appropriate box(es) and submit a detailed description of all the requested information. Begin each item on a separate sheet. Identify the item number and the date of the application in the lower right corner of each page. If you indicate that an appendix to the medical licensing guide will be followed, do not submit the pages, but specify the revision number and date of the referenced guide: Regulatory Guide 10.8 , Rev. _____ Date: _____

7. MEDICAL ISOTOPES COMMITTEE		15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL (Check One)	
Names and Specialties Attached; and		Appendix G Rules Followed; or	
Duties as in Appendix B; or _____ (Check One)		Equivalent Rules Attached	
Equivalent Duties Attached		16. EMERGENCY PROCEDURES (Check One)	
8. TRAINING AND EXPERIENCE		Appendix H Procedures Followed; or	
<input checked="" type="checkbox"/>	Supplements A & B Attached for Each Individual User; and	Equivalent Procedures Attached	
<input checked="" type="checkbox"/>	Supplement A Attached for RSO.	17. AREA SURVEY PROCEDURES (Check One)	
9. INSTRUMENTATION (Check One)		Appendix I Procedures Followed; or	
Appendix C Form Attached; or		Equivalent Procedures Attached	
List by Name and Model Number		18. WASTE DISPOSAL (Check One)	
10. CALIBRATION OF INSTRUMENTS		Appendix J Form Attached; or	
Appendix D Procedures Followed for Survey Instruments; or _____ (Check One)		Equivalent Information Attached	
Equivalent Procedures Attached; and		19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS (Check One)	
Appendix D Procedures Followed for Dose Calibrator; or _____ (Check One)		Appendix K Procedures Followed; or	
Equivalent Procedures Attached		Equivalent Procedures Attached	
11. FACILITIES AND EQUIPMENT		20. THERAPEUTIC USE OF SEALED SOURCES	
Description and Diagram Attached		Detailed Information Attached; and	
12. PERSONNEL TRAINING PROGRAM		Appendix L Procedures Followed; or _____ (Check One)	
Description of Training Attached		Equivalent Procedures Attached	
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL		21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon - 133)	
Detailed Information Attached		Detailed Information Attached	
14. PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS (Check One)		22. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS	
Appendix F Procedures Followed; or		Detailed Information Attached	
Equivalent Procedures Attached		23. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.b	
		Detailed Information Attached	

(3)

24. PERSONNEL MONITORING DEVICES				
TYPE <small>(Check appropriate box)</small>		SUPPLIER	EXCHANGE FREQUENCY	
a. WHOLE BODY	FILM	No change		
	TLD			
	OTHER <small>(Specify)</small>			
b. FINGER	FILM			
	TLD	No change		
	OTHER <small>(Specify)</small>			
c. WRIST	FILM			
	TLD			
	OTHER <small>(Specify)</small>			
d. OTHER <small>(Specify)</small>				

25. FOR PRIVATE PRACTICE APPLICANTS ONLY				
a. HOSPITAL AGREEING TO ACCEPT PATIENTS CONTAINING RADIOACTIVE MATERIAL				
NAME OF HOSPITAL			b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.	
MAILING ADDRESS				
CITY	STATE	ZIP CODE		
c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.				

26. CERTIFICATE <small>(This item must be completed by applicant)</small>	
The applicant and any official executing this certificate on behalf of the applicant named in Item 1a certify that this application is prepared in conformity with Title 10, Code of Federal Regulations, Parts 30 and 35, and that all information contained herein, including any supplements attached hereto, is true and correct to the best of our knowledge and belief.	
a. LICENSE FEE REQUIRED <small>(See Section 170.31, 10 CFR 170)</small>	b. APPLICANT OR CERTIFYING OFFICIAL <small>(Signature)</small>  (1) NAME <small>(Type of Print)</small> KHAIRON M. ALLY, M.D.
(1) LICENSE FEE CATEGORY:	(2) TITLE Chief, Nuclear Medicine Service
(2) LICENSE FEE ENCLOSED: \$ _____	c. DATE 10/20/87

(4)

PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on Form NRC-313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

1. **AUTHORITY** Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
2. **PRINCIPAL PURPOSE(S)** The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.
3. **ROUTINE USES** The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.
4. **WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION** Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.
5. **SYSTEM MANAGER(S) AND ADDRESS** Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

BRUCE T. AUSTIN, Ph.D. (Med. Physicist)

2. STATE OR TERRITORY IN
WHICH LICENSED TO
PRACTICE MEDICINE

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
(a)	See attachment marked "BA" (3 pages)			
(b)	Reference Credentials on File under USNRC Licence Nos. 34-06904-01 and 5NM1603			

Radiation Safety Officer: Training and Experience

Bruce T. Austin, Ph.D.
Medical Physicist and Radiation Safety Officer

Education:

B.A., Chemistry, Grinnel College, Iowa	1968
M.S., Radiation Biology, The University of Iowa	1970
Ph.D., Radiation Biology, The University of Iowa	1973

Functional Training and Experience:

I. Radiation Research Laboratory, The University of Iowa,
Iowa City, Iowa

A. Training - formal course and on the job

1. Principles and practices of radiation protection - four years duration
2. Radioactivity measurements standardization and monitoring techniques and instruments - four years
3. Mathematics and calculations basic to the use and measurement of radioactivity - four years
4. Biological effects of radiation - four years

B. Experience: individual user and/or supervisor

^3H & ^{14}C	millicurie quantities	four years	Tracer methodology
^{125}I & ^{131}I	millicurie quantities	four years	Tracer methodology and clinical diagnosis and therapeutic application
$^{99\text{m}}\text{Tc}$	millicurie quantities	four years	Clinical diagnostic applications
^{2-83}Z	To millicurie quantities	four years	Assorted tracer and applications

Amendment Application
January 6, 1983
Enclosure 1

Page 2

Diagnostic and therapeutic x-ray generators	four years	Imaging and radiation effect studies
14 MEV neutron generator	four years (intermittently)	Activation analysis
JANUS reactor	Argonne National Laboratory	one year Radiation effect studies (intermittently)

II. USAF Radiological Health Laboratory, Wright Patterson Air Force Base, Ohio

Experience: Individual user and Radiation Protection Officer

^{137}Cs	Approximately 200 Curie and smaller sources	two years	Instrument Calibration
^{60}Co	Approximately 50 Curie and smaller sources	two years	Instrument Calibration
^{239}Pu	3 Curie	four years	Instrument Calibration
^{1-83}Z	To millicurie quantities of Byproduct; Source, Special Nuclear, Accelerator Produced, and Naturally Occurring materials	four years	Radiochemical standardization and instrument calibration
	Diagnostic and x-ray generators	four years	Radiation protection/ calibration surveys, and radiation exposure reconstruction

III. Wright State University, Dayton, Ohio

Experience: Authorized user and Radiation Safety Officer

^3H & ^{14}C	millicurie to Curie	six years	Tracer CC Applications
^{2-83}Z	to millicurie quantities	six years	Tracer methodologies
	Diagnostic and Research x-ray generators	Six years	Imaging, x-ray diffraction and radiation effect studies

Amendment Application
January 6, 1983
Enclosure 1



**Veterans
Administration**

Memorandum

"BA"
Pg 3/3


Date: October 28, 1987

From: Bruce T. Austin, Ph.D., Medical Physicist (11)

Subj: License Amendment

To: Khairoon Ally, M.D.,
Chief, Nuclear Medicine Service (115)

1. Enclosed, please find copies of credentials relevant to USNRC review and approval of my appointment as Radiation Safety Officer.
2. If you wish, as an alternative or in supplement, you may reference my credentials on file under USNRC License Nos. 34-06904-01 and SNM1603 - those most relevant to the Medical Center License.


BRUCE T. AUSTIN, Ph.D.

(9-81)

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

Approved by OMB
3150-0041
Expires 9-30-86

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER <i>Benny Allen Winick, D.O.</i>		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE <i>Pa. NM Oh</i>		
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C		
<i>American Board of Internal Medicine</i>		<i>Eligible</i>		
<i>American Board of Endocrinology</i>		<i>Eligible</i>		
<i>American Board of Osteopathic Specialists</i>		<i>Eligible</i>		
<i>Internal Medicine / Endocrinology</i>				
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING		
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D	
a. RADIATION PHYSICS AND INSTRUMENTATION	<i>M.S. Hensley med center</i> <i>7/30 - 8/83</i>	<i>28</i>	<i>16.5</i>	
b. RADIATION PROTECTION	<i>as above</i>	<i>24</i>	<i>12</i>	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	<i>as above</i>	<i>22</i>	<i>12.5</i>	
d. RADIATION BIOLOGY	<i>as above</i>	<i>39</i>	<i>14.5</i>	
e. RADIOPHARMACEUTICAL CHEMISTRY	<i>as above</i>	<i>14</i>	<i>2</i>	
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
<i>I-131</i>	<i>200 mCi</i>	<i>M.S. Hensley med center</i> <i>WPAFB med center</i> <i>VAMC Dayton</i>	<i>7 yrs</i>	<i>therapy for</i> <i>thyrotoxicosis and</i> <i>thyroid cancer</i>

PRECEPTOR STATEMENT

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME

Barry Allen Warner, D.O.

STREET ADDRESS

8904 Deep Forest Lane

CITY

Cincinnati, Oh.

STATE

ZIP CODE

45459

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	10	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-76	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING	35	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

Supplement B (Continued)

PROPOSED PHYSICIAN USER

Benny Allen Wansen, D.O.

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	8	
	TREATMENT OF HYPERTHYROIDISM	20	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

DATES OF TRAINING: From 7/80 - 6/83 a total of 500 hours were spent in

TOTAL NUMBER OF HOURS: clinical radioisotope training

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Richard J. Santen, M.D.

b. NAME OF INSTITUTION

M.S. Hensley med. ctr.

c. MAILING ADDRESS

P.O. Box 950

d. CITY

Hensley Pa 17033

e. MATERIALS LICENSE NUMBER(S)

37-13831

5. PRECEPTOR'S SIGNATURE

Richard J. Santen

7. PRECEPTOR'S NAME (Please type or print)

Richard Santen

8. DATE

8-27-87

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF: 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
FULL NAME		
<u>Benny Allen Wagoner, D.O.</u>		
STREET ADDRESS		
<u>8904 Deep Forest Lane</u>		
CITY	STATE	ZIP CODE
<u>Cantonville, Oh</u>	<u>Oh</u>	<u>43459</u>

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloid)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	2	
	TREATMENT OF HYPERTHYROIDISM	9	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Co-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Co-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Documented on additional preceptor statement from Hershey.

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Khairoun M. Ally, M.D.

b. NAME OF INSTITUTION

VAMC

c. MAILING ADDRESS

4100 W. 3rd St

d. CITY

Durham, N.C. 27705

e. MATERIALS LICENSE NUMBER(S)

34-05015-01

5. PRECEPTOR'S SIGNATURE

Khairoun M. Ally, M.D.

7. PRECEPTOR'S NAME (Please type or print)

Khairoun M. ALLY

8. DATE

9/1/87

FORM NRC-313M-SUPPLEMENT B
(8-78)